Prothena Corporation plc — Q1 2013 Form 10-Q Summary
Business context and reporting period
Unaudited quarterly report for the three months ended March 31, 2013. Prothena is an Ireland-incorporated clinical-stage biotechnology company developing antibody candidates for diseases involving protein misfolding or cell adhesion, including amyloidosis, Parkinson’s disease, autoimmune diseases and metastatic cancers. The business separated from Elan Corporation plc in December 2012 and began operating as a standalone public company.
- Lead candidate NEOD001 entered a Phase 1 trial, with first patient dosing in April 2013, to evaluate safety and tolerability in AL amyloidosis.
- Management planned Phase 1 trials for PRX002 in 2014 and PRX003 in 2015.
- Ordinary shares outstanding at April 30, 2013: 17.679 million.
Financial performance and position
| Metric | Q1 2013 | Q1 2012 | Change |
|---|---|---|---|
| Related-party revenue | $0.171 million | $0.404 million | Down 58% |
| Research and development expense | $5.957 million | $8.757 million | Down 32% |
| General and administrative expense | $3.181 million | $2.458 million | Up 29% |
| Total operating expenses | $9.138 million | $11.215 million | Down 19% |
| Loss from operations | $(8.967) million | $(10.811) million | Improved 17% |
| Net loss | $(8.951) million | $(10.811) million | Improved 17% |
| Basic and diluted loss per share | $(0.51) | $(0.75) | Improved |
| Cash used in operating activities | $(5.103) million | $(8.624) million | Lower use of $3.521 million |
- Cash and cash equivalents were $119.563 million at March 31, 2013, compared with $124.860 million at December 31, 2012.
- Total assets were $124.268 million; total liabilities were $6.479 million; shareholders’ equity was $117.789 million.
- The company had no debt reported in the filing. Current liabilities were $5.086 million and deferred rent was $1.393 million.
- Cash used in investing activities was $0.110 million, primarily for property and equipment. Financing activities used $0.084 million for post-separation adjustments.
- Operating margin was approximately negative 5,244% in Q1 2013, based on $0.171 million of related-party revenue and a $8.967 million operating loss. The comparison is not economically meaningful because revenue was minimal and related-party.
- Money market funds represented $101.3 million of cash equivalents at March 31, 2013.
Material changes versus the prior comparable period
- Revenue declined by $0.233 million because the scope of research and development services provided to Elan was reduced.
- R&D expense declined by $2.800 million, primarily due to lower share-based compensation, personnel costs and external NEOD001 development costs, partly offset by higher PRX002 and PRX003 costs.
- G&A expense increased by $0.723 million. Q1 2013 G&A included professional services, Transitional Services Agreement payments, internal personnel costs and $0.340 million of share-based compensation. Q1 2012 included $2.0 million of allocated centralized Elan support costs, making the comparison less representative of standalone operations.
- Share-based compensation expense fell to $0.340 million from $3.570 million. Approximately $4.8 million of unearned expense remained to be recognized through 2017, subject to changes in awards.
- Net cash used in operating activities improved primarily because of lower R&D spending and favorable working-capital changes.
- The Q1 2012 financial statements were prepared on a carve-out basis and included allocated Elan costs; therefore, period-to-period comparisons may not reflect the company’s current standalone cost structure.
Guidance, outlook, commentary, risks and unusual items
- Management believes existing cash and cash equivalents will fund obligations for at least the next twelve months under current plans, but expects additional capital will eventually be required for continued development and commercialization.
- The company expects continuing operating losses and has not generated significant third-party external revenue. It does not expect any candidate to be commercially available for at least seven years, and some or all candidates may never reach commercialization.
- Future funding may come from equity or debt financings, collaborations, licensing transactions or other arrangements. Financing may be unavailable or dilutive, and debt could impose significant payment obligations and restrictive covenants.
- R&D timing and costs are highly uncertain because of clinical-trial enrollment, safety, efficacy, regulatory, manufacturing and third-party contractor risks. The filing does not provide a specific cost or completion estimate for the NEOD001 Phase 1 trial.
- Clinical trial liability insurance for NEOD001 had a $10.0 million annual aggregate coverage limit, which may not fully cover potential claims.
- The company relies on Elan for substantially all accounts receivable and Q1 2013 related-party revenue. The filing states that credit risk was not considered significant due to Elan’s financial resources.
- No material legal proceedings or off-balance-sheet arrangements were reported. Management concluded that disclosure controls were effective as of March 31, 2013.
Important facts for investors to verify
- Verify the progress, safety findings, enrollment and regulatory status of the NEOD001 Phase 1 trial initiated after quarter-end.
- Assess cash runway against planned spending for NEOD001, PRX002, PRX003 and other discovery programs, including the potential need for additional financing.
- Review the company’s dependence on Elan for related-party revenue, receivables and transitional services, and monitor how this relationship changes.
- Reconcile reported results with standalone operating costs, given the carve-out accounting and $2.0 million of allocated Elan support costs in Q1 2012.
- Monitor dilution from the 1.366 million stock options granted in Q1 2013 and the remaining $4.8 million of unearned share-based compensation.
- Evaluate patent, regulatory, clinical-trial, manufacturing, product-liability and third-party collaboration risks before assigning value to the pipeline.